Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Adicionar filtros








Intervalo de ano
1.
The World Journal of Men's Health ; : 219-225, 2019.
Artigo em Inglês | WPRIM | ID: wpr-742356

RESUMO

PURPOSE: Sperm cryopreservation before cancer treatment is the most effective method to preserve the fertility of male patients. We present our 21 years experience with sperm cryopreservation for cancer patients, including an examination of semen quality, the current status of cryopreserved sperm, and the rate of sperm use for assisted reproductive technology (ART). MATERIALS AND METHODS: A total of 721 cancer patients at Fertility Center of CHA Gangnam Medical Center successfully performed sperm cryopreservation for fertility preservation from January 1996 to December 2016. Medical chart review was used to analyze patient age, marital status, cancer type, semen volume, sperm counts and motility, length of storage, and current banking status. RESULTS: The major cancers of the 721 patients were leukemia (28.4%), lymphoma (18.3%), testis cancer (10.0%). The mean age at cryopreservation was 27.0 years, and 111 patients (15.4%) performed sperm cryopreservation during or after cancer treatment. The mean sperm concentration was 66.7±66.3 ×106/mL and the mean sperm motility was 33.8%±16.3%. During median follow-up duration of 75 months (range, 1–226 months), 44 patients (6.1%) used their banked sperm at our fertility center for ART and 9 patients (1.2%) transferred their banked sperm to another center. The median duration from cryopreservation to use was 51 months (range, 1–158 months). CONCLUSIONS: Sperm cryopreservation before gonadotoxic treatment is the most reliable method to preserve the fertility of male cancer patients. Sperm cryopreservation should be offered as a standard of care for all men planning cancer therapy.


Assuntos
Humanos , Masculino , Criopreservação , Preservação da Fertilidade , Fertilidade , Seguimentos , Leucemia , Linfoma , Estado Civil , Métodos , Técnicas de Reprodução Assistida , Sêmen , Análise do Sêmen , Preservação do Sêmen , Contagem de Espermatozoides , Motilidade dos Espermatozoides , Espermatozoides , Padrão de Cuidado , Neoplasias Testiculares
2.
Clinical and Experimental Reproductive Medicine ; : 173-177, 2019.
Artigo em Inglês | WPRIM | ID: wpr-785642

RESUMO

OBJECTIVE: We investigated the clinical characteristics of men with testosterone replacement therapy (TRT)-induced hypogonadism and its effect on assisted reproductive technology (ART) in infertile couples.METHODS: This study examined the records of 20 consecutive male patients diagnosed with azoospermia or severe oligozoospermia (<5×10⁶/mL) who visited a single infertility center from January 2008 to July 2018. All patients were treated at a primary clinic for erectile dysfunction or androgen deficiency symptoms combined with low serum testosterone. All men received a phosphodiesterase 5 inhibitor and TRT with testosterone undecanoate (Nebido®) or testosterone enanthate (Jenasteron®). Patients older than 50 years or with a chronic medical disease such as diabetes were excluded.RESULTS: The mean age of patients was 37 years and the mean duration of infertility was 16.3±11.6 months. At the initial presentation, eight patients had azoospermia, nine had cryptozoospermia, and three had severe oligozoospermia. Serum follicle-stimulating hormone levels were below 1.0 mIU/mL in most patients. Three ongoing ART programs with female factor infertility were cancelled due to male spermatogenic dysfunction; two of these men had normal semen parameters in the previous cycle. After withholding TRT, serum hormone levels and sperm concentrations returned to normal range after a median duration of 8 months.CONCLUSION: TRT with high-dose testosterone can cause spermatogenic dysfunction due to suppression of the hypothalamic-pituitary-testicular axis, with adverse effects on infertility treatment programs. TRT is therefore contraindicated for infertile couples attempting to conceive, and the patient's desire for fertility must be considered before initiation of TRT in a hypogonadal man.


Assuntos
Feminino , Humanos , Masculino , Azoospermia , Nucleotídeo Cíclico Fosfodiesterase do Tipo 5 , Disfunção Erétil , Características da Família , Fertilidade , Hormônio Foliculoestimulante , Hipogonadismo , Infertilidade , Infertilidade Masculina , Oligospermia , Valores de Referência , Técnicas de Reprodução Assistida , Sêmen , Espermatozoides , Testosterona
3.
Clinical and Experimental Reproductive Medicine ; : 95-98, 2019.
Artigo em Inglês | WPRIM | ID: wpr-763352

RESUMO

Obstructive azoospermia caused by acute epididymitis is usually permanent, and microsurgical vasoepididymostomy is the only reconstructive treatment option. There have been no reports of delayed recovery of sperm count after over 1 year in a patient with obstructive azoospermia related to history of acute epididymitis. We present a young male patient who had azoospermia and a history of acute epididymitis who experienced delayed recovery, with complete restoration of sperm production and the ability to conceive naturally.


Assuntos
Humanos , Masculino , Azoospermia , Epididimite , Infertilidade , Contagem de Espermatozoides , Espermatozoides
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA